Search Within

MSK Grad Students

Formats
  1. Journal Article (1685)
  2. Meeting Abstract (991)
  3. Review (110)
  4. Editorial (43)
  5. Research Letter (37)
  6. Miscellaneous (21)
  7. Correspondence (15)
  8. Conference Paper (12)
  9. Book Section (9)
  10. Guidelines (6)
Groups
  1. GSK Faculty (2053)
  2. Department of Medicine (1647)
  3. Sloan Kettering Institute Postdocs (1633)
  4. Sloan Kettering Institute Faculty (1330)
  5. Center for Molecular Imaging and Biotechnology (CMIB) (1201)
  6. Center for Hematologic Malignancies (1143)

More Groups

People
  1. Sergio Giralt (401)
  2. Miguel-Angel Perales (386)
  3. Parastoo Dahi (305)
  4. Sean Devlin (286)
  5. Doris Ponce (257)
  6. Roni Tamari (214)

More People

Years
  1. 2025 (163)
  2. 2024 (275)
  3. 2023 (313)
  4. 2022 (334)
  5. 2021 (289)
  6. 2020 (378)

More Years

Publications
  1. Blood (311)
  2. Biology of Blood and Marrow Transplantation (165)
  3. Cancer Research (133)
  4. Journal of Clinical Oncology (130)
  5. Nature Communications (96)
  6. Nature (89)

More Publications

Publishers
  1. Nature Publishing Group (447)
  2. American Society of Hematology (350)
  3. Elsevier Inc. (299)
  4. Cell Press (280)
  5. American Association for Cancer Research (269)
  6. American Society of Clinical Oncology (149)

More Publishers

Results (2929)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Development of CAR T cells targeting U5 snRNP200 for the treatment of acute myeloid and B-lymphoid leukemias
    Meeting Abstract

    Fujino, T.; Lewis, J.; Chen, B. Y.; Sievers, Q.; Cai, W.; Yoo, S.; Mathew, S.; Souness, S.; Burns, E. R.; Um, J. S.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Long-term follow up of a prospective pilot study of an α/β T-lymphocyte depleted graft conditioned with a reduced intensity regimen in patients with hematologic malignancies
    Meeting Abstract

    Hughes, C. F. M.; Lin, R. J.; Devlin, S. M.; Shaffer, B. C.; Jakubowski, A. A.; Talla, V.; Saldia, A.; Gyurkocza, B.; Papadopoulos, E. B.; Giralt, S. A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • GVHD therapy with ruxolitinib is frequently associated with cytopenias, but significant decline in hemoglobin level was only observed in non-responders at day 28
    Meeting Abstract

    Gergoudis, S.; Devlin, S. M.; Susman, P.; Singh, A.; Chinapen, S.; Perales, M. A.; Ponce, D. M.
    Blood (2024)

    Fulltext@MSK | Save
  • Efficacy of budesonide monotherapy for low grade GI GVHD after post transplant cyclophosphamide
    Meeting Abstract

    Cook, M.; Vadakkel, G.; Chinapen, S.; Perales, M. A.; Tamari, R.; Papadopoulos, E. B.; Ponce, D. M.; Shaffer, B. C.; Lin, A.
    Blood (2024)

    Fulltext@MSK | Save
  • Utility of circulating tumor DNA (ctDNA) as a molecular biomarker in the phase II trial of imatinib plus binimetinib in patients with treatment-naïve, advanced gastrointestinal stromal tumor (GIST)
    Meeting Abstract

    Kelly, C. M.; Bradic, M.; Saunds, S.; Avutu, V.; Chan, J.; D'Angelo, S. P.; Dickson, M.; Gounder, M.; Keohan, M. L.; Movva, S.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • SAABR: Single arm phase II study of androgen receptor pathway inhibitor (ARPI) + atezolizumab + GnRH analog (ADT) and stereotactic body radiotherapy (SBRT) to the prostate in men with de novo hormone-sensitive metastatic prostate cancer (mHSPC)
    Meeting Abstract

    Rathkopf, D.; Dallos, M.; Stein, M.; Spina, C. S.; Deutsch, I.; Nguyen, C.; Okada, A.; Lloyd, M.; Manarite, J.; McBride, S.
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • An open label phase IIa study evaluating the preliminary efficacy of intratumoural tigilanol tiglate (TT) in advanced and/or metastatic soft tissue sarcoma (STS)
    Meeting Abstract

    Bartlett, E. K.; Li, D.; Shemla, S.; Ariyan, C. E.; Dickinson, S.; Crago, A.; Li, G.; Agaram, N.; D'Angelo, S. P.; Maki, R. G.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Zolbetuximab with gemcitabine + nab-paclitaxel (GN) in first-line treatment of Claudin 18.2–positive metastatic pancreatic cancer (mPC): Phase II, open-label, randomized study
    Meeting Abstract

    Park, W.; O'Reilly, E. M.; Li, C. P.; Oh, D. Y.; Garcia-Carbonero, R.; Roth, G.; Nakajima, T.; Moran, D.; Yang, J.; Li, R.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Phase II trial of Pembrolizumab and OLApaRib (POLAR) maintenance for select patients (pts) with metastatic pancreatic cancer (mPC) with (A) homologous recombination deficiency (HRD), (B) non-core HRD (ncHRD) and (C) exceptional response to platinum
    Meeting Abstract

    Park, W.; O'Connor, C.; Chou, J.; Schwartz, C.; Larsen, M.; Varghese, A.; Yu, K.; Balogun, F.; Yang, J.; Katz, S.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save
  • Persistence and resistance of HER2 amplification after T-DM1 in a basket trial for patients with solid tumors
    Meeting Abstract

    Liu, D.; Arora, K.; Makker, V.; Buonocore, D.; Shen, R.; Yaeger, R.; Ginsberg, M. S.; Yeh, R.; Offin, M. D.; Solit, D.; more...
    Annals of Oncology (2024)

    Fulltext@MSK | Save